Loading
A phase 2 trial of Pembrolizumab in biliary tract cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer is a phase 2 interventional study registered as NCT06978114 by Sichuan Baili Pharmaceutical Co., Ltd., with 46 participants planned, started 2025-06-10 and due to reach its primary completion in 2027-05. Interventions recorded: BL-B01D1 and Pembrolizumab.
Shares SystImmune / Sichuan Biokin, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.